Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Non-Hodgkin

Explore clinical trials studying Lymphoma, Non-Hodgkin. Study availability and eligibility vary by location and protocol.

1,630 public trials 214 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Non-Hodgkin trial results

Active, Not Recruiting

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

NCT05171647

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • City of Hope Cancer Center Duarte, California, United States
  • St. Luke's Hospital Chesterfield, Missouri, United States
  • Ascension Seton Infusion Center Austin, Texas, United States
  • MD Anderson Cancer Center Houston, Texas, United States
View all 52 locations
View Trial Details
Active, Not Recruiting

Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy

NCT01829958

Conditions
Diffuse Large B-Cell Lymphoma (DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack Commack, New York, United States
View Trial Details
Active, Not Recruiting

Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas

NCT05400109

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
  • University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States
View Trial Details
Active, Not Recruiting

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

NCT05618028

Conditions
B Cell Malignancies, Chronic Disease, Chronic Lymphocytic Leukemia, +21 more
Locations
  • University of California Los Angeles Medical Center /ID# 246357 Los Angeles, California, United States
  • Yale University School of Medicine /ID# 259081 New Haven, Connecticut, United States
  • Mount Sinai Medical Center-Miami Beach /ID# 248251 Miami Beach, Florida, United States
  • Fort Wayne Medical Oncology and Hematology, Inc /ID# 250113 Fort Wayne, Indiana, United States
View all 39 locations
View Trial Details
Active, Not Recruiting

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

NCT03913949

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +17 more
Locations
  • Anhui Procincial hospital Hefei, Anhui, China
  • Henan Provincial Oncology Hospital Zhengzhou, Henan, China
  • Zhongnan Hospital of Wuhan University Wuhan, Hubei, China
  • Blood Diseases Hospital Chinese Academy of Medical Sciences Tianjin, Tianjin Municipality, China
View Trial Details
Active, Not Recruiting

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

NCT03075696

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • University of Michigan Ann Arbor, Michigan, United States
  • Washington University St Louis, Missouri, United States
  • Mount Sinai Medical Center New York, United States
  • MSKCC New York, United States
View all 34 locations
View Trial Details
Active, Not Recruiting

Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

NCT04546620

Conditions
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Colchester General Hospital Colchester, Essex, United Kingdom
  • East Kent Hospitals NHS Foundation Trust Canterbury, Kent, United Kingdom
  • Monklands Hospital Airdrie, United Kingdom
  • Victoria Hospital Blackpool, United Kingdom
View all 33 locations
View Trial Details
Active, Not Recruiting

DS-3201b in Participants With Lymphomas

NCT02732275

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +17 more
Locations
  • City of Hope National Medical center Duarte, California, United States
  • Yale University New Haven, Connecticut, United States
  • Emory University Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 20 locations
View Trial Details

Related conditions